A Single-Blind Comparative Clinical Trial of Lymecycline and Amoxycillin in the Treatment of Acute Bronchitis in General Practice

Murphy, J E; Donald, J F; Molla, A Layes

doi:10.1177/030006057600400110

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Medical Research Council's (MRC) five-point scale ranges from patients only being affected by dyspnoea during strenuous exercise (grade 1), to severe dyspnoea preventing patients from leaving the house or getting dressed comfortably (grade 5). 9 This scale has been used for diagnostic evaluation and in clinical trials, 2,10,11 and is still used to compare the categorisations of dyspnoea with the staging of disease severity. 12,13 Unidimensional scales tend to have the advantage of being easy to administer and score.…”

Section: Unidimensional Scales Measuring Dyspnoeamentioning

confidence: 99%

Measuring the effects of COPD on the patient

Jones

Lareau

Mahler

2005

Respiratory Medicine

View full text Add to dashboard Cite

Evaluation of the effectiveness of treatment for chronic obstructive pulmonary disease (COPD) requires the assessment of both clinical and physiological measures. Parameters such as the forced expiratory volume in 1 s are well established in providing an indication of the degree of airflow limitation. However, additional measurements, such as dyspnoea, functional status and health status, are required to provide a complete picture of COPD. Indeed, dyspnoea is the predominant symptom of COPD experienced by the patient, which treatment is designed to reduce. Methods of assessing dyspnoea have developed over the previous five decades. The most widely used instruments for assessing the impact of dyspnoea are the baseline dyspnoea index, the transition dyspnoea index and the Medical Research Council Questionnaire. A more comprehensive approach to the assessment of disability caused by dyspnoea and fatigue is provided by assessments of functional status, such as the pulmonary functional status and dyspnoea questionnaire. Respiratory-specific health status questionnaires, such as the St. George's Respiratory Questionnaire, attempt to capture the wide range of effects of COPD into a single score that reflects the overall impact of the disease. Developing the means to measure the effects of COPD is important, both in terms of understanding disease pathophysiology for research purposes, and in terms of accurately assessing the effects of treatment on the patient. Future developments will include computerising these methodologies to permit faster and more individual patient-centred measurements.

show abstract